目的 探討不同復(fù)方丹參制劑對冠心病心絞痛患者療效、炎性因子及氧化應(yīng)激指標(biāo)的影響。方法 采用隨機(jī)數(shù)字表法將2013年5月—2017年11月陜西省人民醫(yī)院收治的364例冠心病心絞痛患者分為顆粒劑組、膠囊劑組、片劑組及滴丸劑組，每組91例。4組均給予常規(guī)治療，包括給予硝酸甘油、阿司匹林等。在常規(guī)治療基礎(chǔ)上，顆粒劑組、膠囊劑組、片劑組及滴丸劑組分別口服復(fù)方丹參顆粒，1袋/次，3次/d；復(fù)方丹參膠囊，3粒/次，3次/d；復(fù)方丹參片，3片/次，3次/d；復(fù)方丹參滴丸，10丸/次，3次/d。4組均治療3個(gè)月。治療后，比較4組患者的臨床療效、癥狀緩解情況（每天平均心絞痛發(fā)作次數(shù)、平均心絞痛持續(xù)時(shí)間及平均硝酸甘油使用量）和血清炎性因子［超敏C反應(yīng)蛋白（hs-CRP）、白介素-6（IL-6）、脂蛋白相關(guān)磷脂酶A2（Lp-PLA2）及可溶性細(xì)胞間黏附分子－1（sICAM-1）］水平，氧化應(yīng)激指標(biāo)［總抗氧化能力（TAoc）、丙二醛（MDA）、谷胱甘肽過氧化物酶（GSH-PX）及超氧化物歧化酶（SOD）］水平。結(jié)果 治療3個(gè)月后，滴丸劑組總有效率明顯高于顆粒劑組、膠囊劑組及片劑組（P<0.05）。治療3個(gè)月后，4組患者心絞痛發(fā)作次數(shù)、平均心絞痛持續(xù)時(shí)間及平均硝酸甘油使用量均明顯降低（P<0.05），且滴丸劑組均明顯低于其余3組（P<0.05）。治療3個(gè)月后，4組患者h(yuǎn)s-CRP、IL-6、Lp-PLA2和sICAM-1水平均明顯降低（P<0.05），且滴丸劑組均明顯低于其余3組（P<0.05）。治療3個(gè)月后，4組患者T-Aoc、MDA、GSH-PX及SOD水平均明顯改善（P<0.05），且滴丸劑組改善程度均明顯優(yōu)于其余3組（P<0.05）。結(jié)論 與復(fù)方丹參顆粒、復(fù)方丹參膠囊、復(fù)方丹參片相比較，復(fù)方丹參滴丸治療冠心病心絞痛具有更好的療效，且能夠更有效的改善患者癥狀、炎癥情況及機(jī)體氧化應(yīng)激損傷。

Objective To explore the effect of different Compound Danshen Preparation on curative effect, inflammatory factors, and oxidative stress indexes of angina pectoris patients with coronary heart disease. Methods 364 cases of angina pectoris patients with coronary heart disease in Shaanxi Provincial People's Hospital from May 2013 to November 2017 were divided into granule group, capsule group, tablet group and drop pills group, each group had 91 cases. All patients were treated by regular method, including nitroglycerin and aspirin. On the basis of regular method, granule group, capsule group, tablet group and drop pills group were treated by Compound Danshen Granules, 1 bag/time, three times daily, Compound Danshen Capsules, 3 grains/time, three times daily, Compound Danshen Tablets, 3 tablets/time, three times daily, and Compound Danshen Drop Pills, 10 pills/time, three times daily, respectively. Patients in four groups were treated for 3 months. After treatment, the clinical efficacy, clinical symptomatic remissions (mean times of angina pectoris attack, duration of angina pectoris, and the dosage of nitroglycerin), and the levels of serum inflammatory factors (hs CRP, IL-6, Lp-PLA2 and sICAM-1), and the levels of oxidative stress indexes (T-AOC, MDA, GSH-Px, and SOD) in four groups were compared. Results After treatment of 3 months, the total effective rate in the drop pills group was significantly higher than granule group, capsule group and tablet group (P<0.05). After treatment of 3 months, the mean times of angina pectoris attack, duration of angina pectoris, and the dosage of nitroglycerin in the four groups significantly decreased (P<0.05), and the drop pills group were significantly lower than other groups (P<0.05). After treatment of 3 months, the levels of hs-CRP, IL-6, Lp-PLA2 and sICAM-1 in four groups were significantly decreased (P<0.05), and the indexes in the drop pills group were significantly lower than other three groups (P<0.05). After treatment of 3 months, the levels of T-Aoc, MDA, GSHPX and SOD in four groups were significantly promoted, and the these indexes in the drop pills group were significantly better than the other three groups (P<0.05). Conclusion Compared with Compound Danshen Granules, Compound Danshen Capsules, and Compound Danshen Tablets, Compound Danshen Drop Pills has better effects in treatment of angina pectoris patients with coronary heart disease, could release the patient's symptoms, and improve the inflammation and oxidative stress of patient.

R972